Skip to main content

Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab



We recently reported a 56% objective response rate in patients with advanced Merkel cell carcinoma (MCC) receiving pembrolizumab. However, a biomarker predicting clinical response was not identified.


Pretreatment FFPE tumor specimens (n = 26) were stained for CD8, PD-L1, and PD-1 by immunohistochemistry/immunofluorescence (IHC/IF), and the density and distribution of positive cells was quantified to determine the associations with anti-PD-1 response. Multiplex IF was used to test a separate cohort of MCC archival specimens (n = 16), to identify cell types expressing PD-1.


Tumors from patients who responded to anti-PD-1 showed higher densities of PD-1+ and PD-L1+ cells when compared to non-responders (median cells/mm2, 70.7 vs. 6.7, p = 0.03; and 855.4 vs. 245.0, p = 0.02, respectively). There was no significant association of CD8+ cell density with clinical response. Quantification of PD-1+ cells located within 20 μm of a PD-L1+ cell showed that PD-1/PD-L1 proximity was associated with clinical response (p = 0.03), but CD8/PD-L1 proximity was not. CD4+ and CD8+ cells in the TME expressed similar amounts of PD-1.


While the binomial presence or absence of PD-L1 expression in the TME was not sufficient to predict response to anti-PD-1 in patients with MCC, we show that quantitative assessments of PD-1+ and PD-L1+ cell densities as well as the geographic interactions between these two cell populations correlate with clinical response. Cell types expressing PD-1 in the TME include CD8+ T-cells, CD4+ T-cells, Tregs, and CD20+ B-cells, supporting the notion that multiple cell types may potentiate tumor regression following PD-1 blockade.


Merkel cell carcinoma (MCC) is an aggressive uncommon cutaneous malignancy, for which two main etiologies have been described: Merkel cell polyomavirus (MCPyV) infection, associated with approximately 80% of cases; and ultraviolet light exposure, which accounts for the remaining 20% [1]. Patients with MCC often exhibit oligoclonal lymphocyte-mediated and antibody-mediated immunity against MCC tumor antigens [2,3,4], with complex arrangements of immune cells, including B cells, CD4+ and CD8+ T cells, macrophages and regulatory T cells [5]. CD8+ tumor-infiltrating lymphocytes (TIL) [4, 6] and tumor cell PD-L1 expression [7] have been associated with improved patient survival, indicating that the immune system is able to exert some control over this aggressive neoplasm.

PD-1 is an inhibitory receptor expressed on various immune cell subsets, including CD8+ and CD4+ T cells, B cells, and natural killer cells [8]. The interaction between PD-1 and its ligands downregulates immune cell activation, proliferation, survival and cytokine production [8, 9]. For this reason, therapeutic blockade of the PD-1/PD-L1 checkpoint has been embraced as a strategy to enhance antitumor immunity, with durable efficacy in some patients with multiple tumor types [10]. We recently reported that patients with advanced MCC receiving first-line treatment with pembrolizumab (anti-PD-1) experienced an objective response rate of 56% [11]. Also, patients treated with avelumab (anti-PD-L1) showed a 66% and 32% response rate when received in the first and second/third line settings, [12, 13] respectively. Many efforts to discover and validate biomarkers of response to anti-PD-(L)1 are currently underway. The best-studied biomarker is tumor PD-L1 protein expression, measured by immunohistochemistry (IHC) and graded by a pathologist as either “positive” or “negative”. Across multiple solid tumor types, it has been shown that patients whose pre-treatment tumors are PD-L1+ demonstrate an enriched objective response rate to anti-PD-(L)1, compared to their PD-L1- counterparts [14]. However, we found that the simple presence or absence of tumor cell PD-L1 expression in MCC did not correlate with anti-PD-1 response [11]. In the current study, we expanded our histopathologic analysis of the MCC TME using next-generation digital pathology-assisted quantitative methods, including topographic quantitative density analyses and spatial proximity analyses, to assess the density, distribution, and proximity of CD8+, PD-1+ and PD-L1+ cell populations. We found that the density of PD-1+ cells or PD-L1+ cells, and the number of PD-1+ cells in close proximity to PD-L1+ cells, each correlated with clinical response. While it is assumed that PD-1 is mostly involved in regulation of CD8+ T-cell activity in the TME, we discerned multiple immune cell subsets which may contribute to PD-1 biomarker relevance.


Case selection

This study was approved by the institutional review board of each participating institution. All participants provided written informed consent. Twenty-six patients with stage IIIB or IV MCC were enrolled from January 2015 until December 2015 and received at least one dose of pembrolizumab on a phase 2, single-cohort, multicenter clinical trial [11]. Objective responses were assessed by the investigators according to RECIST, version 1.1 [15]. A patient was considered to have an objective response to therapy if they demonstrated either a complete response (CR) or partial response (PR), per data analysis on 08/01/2016. A single representative pre-treatment formalin-fixed paraffin-embedded (FFPE) tumor specimen was chosen from each patient for additional studies. The minimum criteria for inclusion was a contiguous viable tumor deposit measuring >1 mm2 in size.

A second cohort of 16 FFPE specimens acquired between 11/2002–04/2011 from 16 unique patients with stage IA- IV MCC was obtained from the Johns Hopkins Hospital (JHH) surgical pathology archives [7]. This cohort did not receive anti-PD-1 therapy. H&E slides from each case were reviewed by a board-certified dermatopathologist to confirm the diagnosis. A single representative FFPE tumor block was chosen for additional studies.

Single IHC or IF stains

Serial 4 μm FFPE pre-treatment tumor specimens from patients receiving anti-PD-1 were stained for CD8 (n = 23/26, mAb clone 144B, Dako, Carpinteria, CA), PD-1 (n = 16/26, goat polyclonal Ab, R&D Systems, Minneapolis, MN) or PD-L1 (n = 25/26, mAb clone 22C3, Merck Research Laboratories, White House Station, NJ) by IHC/IF, as previously described [11]. Archival specimens from patients not treated with anti-PD-1 were stained for NKp46 using IHC. Appropriate positive and negative controls for each marker were run with every batch.

Pathologist interpretation of PD-L1 IHC

PD-L1 expression on tumor cells (TC) and immune cells (IC) was scored by two pathologists blinded to patient outcomes (AS, JC). PD-L1 expression was assessed as none (< 1%), 1%, 2–4%, 5–9%, 10–19%, and at increasing 10% intervals. PD-L1+ TC or IC had ≥1% positive cells.

Digital image analysis for cell densities and proximity analysis using single IHC/IF stains

Slides stained for PD-L1, PD-1 or CD8 were scanned using Aperio ScanScope (Leica Biosystems Imaging, Buffalo, IL). NKp46-stained slides were scanned using a NanoZoomer XR (Hamamatsu Photonics, Hamamatsu City, Japan). The resultant slide images were assessed using digital image analysis software (HALO V2.0, Indica Labs, Corrales, NM). The tumor border was annotated by a pathologist, and the area encompassed by this region was designated as intratumoral (IT). A 100 μm distance beyond the tumor-stroma interface was designated as the peritumoral (PT) region, Fig. 1. The number of positive cells per mm2 displaying CD8, PD-1, PD-L1 or NKp46 was assessed as a continuous variable in the IT, PT or total (PT and IT) TME regions. PD-L1 expression was quantified in the total fraction of tissue surface area (total pixels positive/total pixels). Acellular and necrotic areas were excluded from analysis.

Fig. 1

Tumor regions were annotated on high-resolution digital scans of slides stained by IHC/IF. a Peritumoral (PT, 100 um) and intratumoral (IT) regions were annotated. b Representative images for CD8 (brown), PD-1 (green) and PD-L1 (brown) staining from a non-responder (NR) and complete responder (CR)

To determine the proximity between cell membranes displaying PD-L1 and either PD-1 or CD8, we used the Serial Sections Alignment tool and Spatial Analysis Module in HALO. Specifically, serial sections that had been stained for the markers of interest were registered, i.e., Z-stacked, allowing for the assessment of two markers originally detected on two consecutive slides. The algorithm works by calculating the number of cells within a given distance of another cell. First, the number of CD8+ or PD-1+ cells with their cell surfaces < 20 μm from of a PD-L1+ cell was determined across the total TME (defined as the IT and PT regions combined) [16]. Then, the number of PD-L1+ cells with their cell surfaces < 20 um from a CD8+ cell or a PD-1+ cell was assessed.

Multiplex immunofluorescence (mIF)

Tumor specimens were available for additional study with mIF from 6 patients who received anti-PD-1 [progressive disease (PD), n = 1; PR, n = 4; CR, n = 1]. Specimens were stained by mIF for CD8, PD-1, PD-L1, CD68, FoxP3 and neuron-specific enolase (NSE, tumor cells) as previously described [11]. In addition, 16 archival MCC tumor specimens from patients who did not receive anti-PD-1 therapy were stained by mIF for PD-1, CD8, CD4, CD20, Fox-P3, and NSE.

Panel 1: (PD-L1, PD-1, NSE, CD68, CD8, DAPI)

4 μm-thick slides from FFPE tissue were heated at 57 °C overnight, and the residual paraffin was removed using xylene. After tissue rehydration using a series of graded alcohols to distilled water, antigen retrieval was performed using Tris-EDTA buffer and microwave treatment. Slides were washed, and blocking was performed with 3% H2O2 blocking solution followed by Dako antibody diluent. The first primary antibody (“Position 1” in Table 1) was then applied. Opal polymer HRP Ms. + Rb (Perkin Elmer, Hopkington, MA) was used as the secondary antibody. The slides were washed, and the tyramide signal amplification (TSA)-dye (Opal 7 color kit, Perkin Elmer, Hopkington, MA) for Position 1 was applied. Slides were then microwaved to strip the primary and secondary antibodies, washed, and blocked again using blocking solution. The second primary antibody (“Position 2”) was applied, and the process was repeated through amplification of the sixth primary antibody labeling. After the last step of antibody striping, DAPI was applied. After unbound DAPI was washed off, slides were coverslipped using VectaShield Antifade Mounting Medium (Vector Labs, Burlingame, CA). Panel 1 was performed using a manual method for staining.

Table 1 Primary antibody information for Multiplex IHC/IF panels

Panel 2: (PD-1, NSE, CD4, CD8, CD20, FoxP3, DAPI)

An automated protocol was used for Panel 2. Slides were heated at 60 °C for 30 min then Dewax (Leica Biosystems, Buffalo Grove, IL) applied to remove any paraffin. Antigen retrieval was performed using ER2 (Leica Biosystems, Buffalo Grove, IL) at 100 °C for 40 min followed by a washing step. Non-specific staining was blocked using Blocking/Ab Diluent (Perkin Elmer, Hopkington, MA) for 5 min, then the first primary antibody was applied, Table 1, followed by a washing step. ImmPRESS™ HRP Anti-Mouse IgG (Vector Laboratories, Burlingame, CA) was applied for 15 min. The slides were washed, and the TSA-dye (Opal 7 color kit, Perkin Elmer, Hopkington, MA) for Position 1 was applied. Slides were then heated using ER1 (Leica Biosystems, Buffalo Grove, IL) at 95 °C for 20 min to strip the primary and secondary antibodies, washed, and blocked again using Blocking/Ab Diluent. The second primary antibody (Position 2) was applied, followed by Opal polymer HRP Ms. + Rb (Perkin Elmer, Hopkington, MA). The corresponding Opal was applied, and the antibodies stripped. The staining process was repeated for positions 3–6. After the last step of antibody striping, the slides were removed from the Bond Rx (Leica Biosystems, Buffalo Grove, IL), and DAPI was applied. After unbound DAPI was washed off, slides were coverslipped using ProLong™ Diamond Antifade Mountant (Life Technologies, Waltham, MA).

Slide scanning and analysis for multispectral IF/IHC

Stained slides were scanned using the Vectra 3.0 Quantitative Pathology Imaging System (Perkin Elmer, Waltham, MA). Ten high-power fields (HPF) along the tumor-stroma interface enriched in immune cells (“hot-spots”) were chosen for analysis in each specimen. InForm 2.3 Image Analysis software (Perkin Elmer) was used for spectral unmixing, cell segmentation, and identification and quantification of cellular subsets. The fraction of cells in each lineage was normalized by the number of tumor cells in each analyzed field.

Tumor Merkel cell Polyomavirus (MCPyV) status

Tumor specimens were assessed for the presence of MCPyV as previously described [7, 11].


Data are reported as the median and range in the text and median ± IQR for figures. Two-sided Mann–Whitney U-test was used to compare tumor-infiltrating immune cell densities between responders (R) vs. non-responders (NR); patients with PD-L1+ vs. PD-L1(−) tumors; and MCPyV+ vs. MCPyV- tumors. Chi-square test was used to compare the fraction of PD-L1+ tumors and the PD-L1 expression gradient (TC and IC) between R vs. NR, and MCPyV+ vs. MCPyV- tumors.


Patient and specimen characteristics

Twenty-six MCC patients received anti-PD-1 therapy and had pretreatment tumor tissue available for study. As of data analysis on 08/01/2016, 17 demonstrated an objective response (CR = 5, PR = 12), 8 showed no response (1 with stable disease and 7 with PD), and one patient demonstrated a transient PR that did not meet RECIST criteria. Fourteen tumors were primary lesions and twelve were metastases. The median interval between specimen acquisition and treatment initiation was 5 months (range 7 days - 8 years), with 85% of the specimens in the cohort being taken within 2 years of treatment initiation. PD-L1 IHC was performed on 25/26 specimens, CD8 IHC on 23/26, and PD-1 IF on 16/26, depending on tissue availability. The median PD-1+ and CD8+ cell densities in patients demonstrating CR vs. PR were not significantly different, thus supporting the grouping of these patients as “Responders”. The density of PD-1+ and CD8+ cells also did not differ by whether the studied specimen was from a primary lesion or a metastasis. Six specimens had sufficient material for IF multiplexing with a panel for NSE, PD-L1, PD-1, CD68, CD8, and FoxP3 expression.

To discern which cell types in the MCC TME express PD-1, a second cohort of 16 archival surgical pathology specimens was studied. Six specimens were from primary lesions and 10 from metastases. The archival specimens were previously characterized with regard to MCPyV status, PT CD8+ density, and tumor cell PD-L1 expression, and these parameters were shown to significantly associate with each other [7]. Among 26 patients who received anti-PD-1 therapy, similar findings were observed, Additional file 1: Figure S1A.

The density of PD-1+ cells, but not CD8+ cells or viral status, correlates with response to anti-PD-1

We evaluated the correlation between the density and distribution of PD-1+ and CD8+ cells and response to anti-PD-1. The total density of PD-1+ cells (PT + IT) was significantly higher in R vs. NR [median number of positive cells/mm2(range) 70.7(20.2–203.4) vs. 6.7(0–70), p = 0.03], Fig. 2a. In contrast, the total density of CD8+ cells did not associate with response status [R 264/mm2 (8.6–1712) vs. NR 216.6/mm2(7.0–517.0), p = 0.17], Fig. 2b. We further subdivided the TME into PT and IT regions and analyzed the PD-1+ and CD8+ cell densities in each area separately, and similar results were observed, Additional file 1: Figure S2. We also found that while CD8+ cell densities, especially peritumoral, associated with the presence of MCPyV, PD-1+ cell densities and response to therapy did not, Additional file 1: Figure S1b and Nghiem, et al. 2016. These findings indicate that CD8+ and PD-1+ cell densities are not interchangeable biomarkers of response to anti-PD-1 in patients with MCC.

Fig. 2

PD-1+ and PD-L1+ cell densities correlate with clinical response to anti-PD-1. a Responders (R) had significantly higher median densities (±IQR) of PD-1+ when compared to non-responders (NR) b CD8+ cell densities were not significantly different between the two groups. c, d R had higher median densities (±IQR) of PD-L1+ cells as well as PD-L1+ tissue area when compared to NR. *p < 0.05. Assessments were made on the total TME (IT+PT). Results for each individual region are presented in Additional file 1: Figures S2 and Figure S4

PD-L1 density and total PD-L1 expression area correlate with response to anti-PD-1

PD-L1 status on tumor cells (TC) + immune cells (IC), or TC or IC alone, was assigned by a pathologist as PD-L1+ or PD-L1- using a 1% threshold. An association with clinical response was not observed, Additional file 1: Figure S3A. When the percentage of all cells (TC + IC) in the TME expressing PD-L1, as well as the percentage of TC or IC, were studied at discrete intervals rather than binomially, there was still no association with response, Additional file 1: Figure S3B.

We next evaluated the correlation between digitally-quantified PD-L1 expression (a continous variable) and response to anti-PD-1. Increased densities of PD-L1+ cells (Fig. 2c) and an increased fraction of tissue surface area expressing PD-L1 (Fig. 2d) both correlated with improved response to PD-1 checkpoint inhibition (p = 0.02, p = 0.03, respectively). Similar associations held when the IT and PT regions were examined separately, Additional file 1: Figure S4.

To further dissect potential associations between the degree of CD8 cytotoxic T-cell infiltration and PD-1/PD-L1 expression, the cohort was divided into quartiles of PD-L1+, CD8+ and PD-1+ total cell densities. All patients in the highest quartile for each of these three markers demonstrated a response, Additional file 1: Figure S5. None of the patients with the lowest PD-1+ cell density responded to therapy, while only one patient among 5 in the lowest quartile of PD-L1 expression demonstrated a response. In contrast, several patients in the lowest quartile of CD8+ cell density showed a response. True comparison metrics of the sensitivity and specificity of these different markers will require studying larger cohorts, but these early findings suggest that PD-1+ cell density in pretreatment tumor biopsies may be a better predictor of response than PD-L1+ or CD8+ cell density.

The density of PD-1+ lymphocytes adjacent to PD-L1+ cells correlates with clinical response to anti-PD-1 therapy

We have previously reported examples of constitutive PD-L1 expression in the TME, i.e., not associated with an immune infiltrate [7, 17,18,19,20]. We posit that this pattern may explain why a proportion of patients with PD-L1+ tumors do not respond to anti-PD-1/PD-L1, [14, 21] as it is adaptive PD-L1 expression that indicates an endogenous antitumor immunity [22]. One way to denote adaptive (as opposed to constitutive) PD-L1 expression is the close proximity of PD-L1+ cells in the TME to TILs [17]. As such, we calculated the density of PD-1+ or CD8+ TILs proximate to a PD-L1+ cell, Fig. 3a, as well as the density of PD-L1+ cells proximate to a PD-1+ or CD8 + cell. The density of PD-1+ cells adjacent to a PD-L1+ cell was significantly higher in R vs. NR [69.9/mm2(10.5–141.8) vs. 5.15/mm2(0–32.4), p = 0.03], Fig. 3b. In contrast, the density of CD8+ cells in close proximity to a PD-L1+ cell was not correlated with clinical response to anti-PD-1 therapy [R 326.9/mm2(67.3–748.8) vs. NR 152/mm2(1–593.7), p = 0.46]. When the transposed metric of PD-L1+ cell density proximate to a PD-1+ or CD8 + cell was assessed for the relationship to response, similar results were observed, Additional file 1: Figure S6. We next controlled for the density of PD-1+ and PD-L1+ cells in each sample, and Responders still exhibited a significantly higher density of PD-1+ cells in proximity to PD-L1+ cells than Non-Responders, indicating that the proximity measurement reflects more than simply another representation of PD-1+ and PD-L1+ cell density.

Fig. 3

The density of PD-1+ cells adjacent to a PD-L1+ cell correlates with clinical response to anti-PD-1. a Representative composite image depicting proximity analysis between PD-1+ and PD-L1+ cells performed using the HALO software Spatial Analysis module, Supplemental Methods. The distance between each PD-1+ cell and the nearest PD-L1+ cell (green circles) was calculated, and only those at a distance ≤20 μm (black lines) are quantified (red circles). b Responders (R) had significantly higher median densities (±IQR) of PD-1+, but not CD8+, cells interacting with PD-L1+ cells compared to non-responders (NR). *p < 0.05. The density of PD-L1+ cells within  20 μm of a PD-1+ or CD8+ cell was also calculated, and a similar association with response was observed, Additional file 1: Figure S6

Preliminary results have also been reported noting the association between PD-1/PD-L1 ‘interaction’ and response to anti-PD-1 therapy in patients with melanoma [23].

Multiplex analysis demonstrates that PD-1 is expressed on multiple cell types in MCC

We performed multiplex IHC/IF on six pre-treatment specimens from patients receiving anti-PD-1 therapy to further characterize the MCC TME. We observed that while a substantial population of cells expressed both CD8 and PD-1, there were subpopulations that expressed one or the other marker, Fig. 4a. PD-1 can be expressed not only by CD8+ but also by CD4+, CD20+, Treg and NK cells. As such, a second multiplex panel was designed to assess the relative proportion of PD-1 expressed by these different immune cell subsets in a cohort of archival MCC specimens, Fig. 4b. A NK marker was not included in the multiplex panel due to the very low density of NK cells in the MCC specimens shown on single IHC staining using anti-NKp46 (median density 1 cell/mm2).

Fig. 4

Multiplex immunofluorescence studies demonstrate that PD-1 is expressed on multiple cell types in MCC, including CD8+ cells, CD4+ cells, Treg (CD4 + FoxP3+), CD20+ B-cells, and even sometimes on tumor cells. a Representative photomicrograph of multiplex panel (CD8, yellow; CD68, magenta; FoxP3, red; NSE (tumor), orange; PD-1, cyan; PD-L1, green and DAPI) from a responder in the cohort of patients treated with anti-PD-1. Higher magnification photomicrograph shows that while there is a significant proportion of PD-1+/CD8+ cells (arrow), there are also PD-1+ cells that are CD8- (arrowhead), and CD8+ cells that are PD-1- (asterisk). Left and right panels: 200× and 400× original magnification, respectively. b A second multiplex panel (PD-1, cyan; CD8, yellow; CD4, magenta; FoxP3, red; CD20, white; NSE (tumor), orange, and DAPI) was applied to archival MCC specimens to further characterize cell types expressing PD-1. Left panel: Representative photomicrograph showing host-tumor interface, 200× original magnification. Upper-right panel (1): Cell types expressing PD-1 include CD4 + FoxP3+ cells (arrow) and PD-1 + FoxP3- (arrowhead) cells, 400× original magnification. Lower-right panel (2): CD20+ B-cells (arrowhead) were also noted to express PD-1. (only CD20 and PD-1 channels are shown in the inset, 400× original magnfication). c In one case, low-level, constitutive PD-1 expression on nearly every tumor cell was observed (arrowhead). High levels of PD-1 expression were also seen on TIL (arrow). d PD-1+ cell densities across n = 16 tumor specimens show that PD-1 expression on multiple cell types is observed across different levels of inflammation. The virus status of each specimen is displayed below each specimen number

The median density of CD8 + PD-1+ cells was 46.4/mm2 (range 0.1–199.4), and the median density of CD4 + PD-1+ cells (Treg and Teff) was similar [50.5/mm2(0.0–278.0)]. On average, FoxP3+ cells represented approximately 22% of the CD4 + PD-1+ population. Scattered CD20 + PD-1+ cells were also found [median 5.3/mm2(0–30.2)]. One exceptional case demonstrated broad, constitutive PD-1 expression on tumor cells, Fig. 4c. PD-1 expression on multiple immune cell types was observed and was independent of the degree of inflammation or viral status, Fig. 4d.


MCC appears to be highly responsive to anti-PD-1 therapy, regardless of viral status. Although anti-PD-1 responsiveness in some other cancer types has been correlated with PD-L1 expression (“positive” or “negative”) in pretreatment tumor specimens; this has not been shown for MCC [11]. In the current study, we used sophisticated digital image analysis for cell density along with cartographic assessments and found that higher-resolution digitally-assisted quantitative measurements of the PD-1/PD-L1 axis do, in fact, associate with response to therapy. Significant factors include PD-1+ cell density, PD-L1+ cell density, total surface area within the tumor mass displaying PD-L1, and the expression of PD-1 in close proximity to a PD-L1+ cell. Importantly, we also showed a divergent result for CD8+ cells, whereby neither CD8+ cell densities nor the juxtaposition of CD8+ cells to PD-L1+ cells correlate with response in this setting.

Galon and colleagues demonstrated the prognostic utility of quantitative density assessments of lymphocyte subsets in specific geographic tumor regions for patients with colorectal carcinoma. In their seminal studies, they identified CD3+, CD8+ and CD45RO+ cells in the IT and PT regions with IHC and showed that the “Immunoscore” tiered scoring system based on cell density measurements in these areas had the power to not only augment, but sometimes surpass the predictive value of TNM staging [24, 25]. Newly available multiplexed imaging platforms have facilitated even more finely resolved spatial metrics, allowing for the enumeration of relationships between individual cells. For example, studies in pancreatic carcinoma and head and neck squamous cell carcinoma (HNSCC) have shown the association between improved prognosis and proximity of specific cell types, e.g., CD8+ cells adjacent to cancer cells, and between the number of CD8+ cells next to a PD-L1+ or Treg cell, respectively [26, 16]. Similar approaches were used to map the PD-L1+ microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma [27].

In addition to assisting with prognostication, immune cell density measurements in the IT and PT regions have been studied as predictive biomarkers for response to anti-PD-1 [22, 28, 29]. The emphasis in most of the studies to date has been on CD8, rather than PD-1 expression. Our findings suggest that the precise quantification of PD-1+ cell densities could be of value to predict the response to anti-PD-1 therapy. Because PD-1 is the direct target of anti-PD-1 drugs, it stands to reason that the amount of PD-1 in the TME may be a key component of next generation biomarker panels. More specifically, anti-PD-1 agents are thought to exert their action by disrupting the PD-1/PD-L1 interface. By adding a distance assessment between these two molecules, we provide a more explicit marker of the PD-1/PD-L1 interaction. This effectively ‘corrects’ for the potential expression of one immunoactive partner too far away from a likely receptor-ligand pairing or in the absence of the other, for example, in the case of oncogene-driven or “constitutive” tumor expression.

To our knowledge, this is the first study reporting an association between PD-1+ cells densities and proximity to a PD-L1+ cell and reponse to anti-PD-1 treatment. One previous study assessed PD-1/PD-L1 distance and association with response to anti-PD-1 in patients with melanoma but reported a co-expression score (number of microscopic fields/random disks where both PD-1 and PD-L1 were expressed) [22]. Such an approach does not provide an actual distance between PD-1+ and PD-L1+ cells, and in fact, could erroneously count cells that are dual positive for PD-1 and PD-L1. In that study, the CD8 T-cells also represented the primary cellular source of PD-1 expression.

The differential association between PD-1+ and CD8+ TIL densities with response to anti-PD-1 in MCC prompted us to explore other cell types in the MCC TME expressing PD-1. We found that in addition to CD8+ cells and a singular case of constitutive tumor cell expression, PD-1 was frequently expressed on CD4+ effector cells, Tregs, and occasional CD20+ B-cells. In fact, approximately half of the PD-1+ TILs were CD4+ (Teff or Treg), which is consistent with studies of archival HNSCC, ovarian cancer, and Hodgkin lymphoma FFPE specimens studied by IHC/IF; [27, 30,31,32] and melanoma, renal cell carcinoma, and MCC specimens studied by flow cytometry [33,34,35]. In vitro studies show that PD-L1 engagement of PD-1 receptors on CD4+ cells causes T-cell dysfunction. CD4+ helping capacities (e.g., IFN-γ and TNF-α production which promote CD8+ T-cell effector programs) can be restored following administration of anti-PD-1 [36, 37]. Patients with advanced melanoma treated with pembrolizumab showed increased Ki-67 expression not only on CD8+ cells, but also CD4+ cell populations, lending in vivo support to these in vitro findings [38]. Intriguing studies suggest that antigen-specific CD4+ cells may assume cytotoxic anti-tumor capabilities following immune checkpoint blockade [39, 40]. This mechanism may be particularly relevant in patients with MCC and Hodgkin lymphoma, both of which demonstrate high response rates to PD-1/PD-L1 checkpoint blockade despite reduced MHC class I expression [41, 42]. The functional role of PD-1 on B-cells and Tregs is not as well studied, but recent results suggest that anti-PD-1 antibodies may also exert anti-tumor functions by arresting suppressive B-cells and T-cells, both of which express high levels of PD-1 [43, 44].

MCC is an extremely rare cancer, affecting fewer than 3000 patients each year in the US, and as such, the primary limitation of this study is the number of specimens and amount of material per specimen available for study. Our findings will need to be confirmed in larger MCC cohorts. Due to the limited FFPE material, we were not able to apply our multiplex panels on specimens from patients treated with anti-PD-1. Thus we were not able to assess relative impact of PD-1 expression on CD8+ and CD4+ cells as well as PD-L1 expression on macrophages and tumor cells as they relate to anti-PD-1 response. Lastly, it will also likely be of value to study on-treatment specimens, which have the potential to further inform mechanisms of response and resistance to anti-PD-1 in this tumor type.


The complexity of the TME has surpassed the digital reads of single-stain IHC as positive vs. negative. Value is gained by quantitating the density of cells expressing PD-L1 or PD-1. The addition of spatial metrics, such as the density of PD-1+ cells within a given distance of a PD-L1+ cell, adds a new feature to predictive biomarkers. By incorporating both partners of the receptor-ligand pair, this parameter more accurately reflects the fundamental mechanism underlying PD-1/PD-L1 blockade. Lastly, evolving multiplexing technologies facilitate studies of marker co-expression. We were able to use these techniques to identify cell types beyond CD8 in the MCC TME expressing PD-1. While future studies are needed to characterize the relative contributions of each cell type participating in the anti-tumor response, our study supports the evolving concept that lymphocytic populations beyond CD8+ cytotoxic T-cells may promote tumor regression following anti-PD-1 administration.


  1. 1.

    Becker JC, Stang A, DeCaprio JA, Cerroni L, Lebbé C, Veness M, et al. Merkel cell carcinoma. Nat Rev Dis Primer. 2017;3:17077.

    Article  Google Scholar 

  2. 2.

    Carter JJ, Paulson KG, Wipf GC, Miranda D, Madeleine MM, Johnson LG, et al. Association of Merkel cell polyomavirus-specific antibodies with Merkel cell carcinoma. J Natl Cancer Inst. 2009;101:1510–22.

    CAS  Article  Google Scholar 

  3. 3.

    Sihto H, Böhling T, Kavola H, Koljonen V, Salmi M, Jalkanen S, et al. Tumor infiltrating immune cells and outcome of Merkel cell carcinoma: a population-based study. Clin Cancer Res. 2012;18:2872–81.

    CAS  Article  Google Scholar 

  4. 4.

    Feldmeyer L, Hudgens CW, Ray-Lyons G, Nagarajan P, Aung PP, Curry JL, et al. Density, distribution, and composition of immune infiltrates correlate with survival in Merkel cell carcinoma. Clin Cancer Res. 2016;22:5553–63.

    CAS  Article  Google Scholar 

  5. 5.

    Walsh NM, Fleming KE, Hanly JG, Dakin Hache K, Doucette S, Ferrara G, et al. A morphological and immunophenotypic map of the immune response in Merkel cell carcinoma. Hum Pathol. 2016;52:190–6.

    CAS  Article  Google Scholar 

  6. 6.

    Paulson KG, Iyer JG, Simonson WT, Blom A, Thibodeau RM, Schmidt M, et al. CD8+ lymphocyte intratumoral infiltration as a stage-independent predictor of Merkel cell carcinoma survival: a population-based study. Am J Clin Pathol. 2014;142:452–8.

    Article  Google Scholar 

  7. 7.

    Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res. 2013;1:54–63.

    CAS  Article  Google Scholar 

  8. 8.

    Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.

    CAS  Article  Google Scholar 

  9. 9.

    Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18:153-67.

    Article  Google Scholar 

  10. 10.

    Topalian SL. Targeting immune checkpoints in Cancer therapy. JAMA. 2017;318:1647–8.

    Article  Google Scholar 

  11. 11.

    Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 blockade with Pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374:2542–52.

    CAS  Article  Google Scholar 

  12. 12.

    Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D’Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17:1374–85.

    CAS  Article  Google Scholar 

  13. 13.

    D’Angelo SP, Russell J, Lebbé C, Chmielowski B, Gambichler T, Grob J-J, et al. Efficacy and safety of first-line Avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial. JAMA Oncol. 2018.

  14. 14.

    Giraldo NA, Taube JM. PD-L1 and Other Immunological Diagnosis Tools. Oncoimmunology [Internet]. Springer, Cham; 2018 [cited 2017 Dec 19]. p. 371–85. Available from:

  15. 15.

    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

    CAS  Article  Google Scholar 

  16. 16.

    Feng Z, Bethmann D, Kappler M, Ballesteros-Merino C, Eckert A, Bell RB, et al. Multiparametric immune profiling in HPV oral squamous cell cancer. JCI Insight [Internet]. 2017 [cited 2017 Oct 10];2. Available from:

  17. 17.

    Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4:127ra37.

    Article  Google Scholar 

  18. 18.

    Rodić N, Anders RA, Eshleman JR, Lin M-T, Xu H, Kim JH, et al. PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation. Cancer Immunol Res. 2015;3:110–5.

    Article  Google Scholar 

  19. 19.

    Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:275–87.

    CAS  Article  Google Scholar 

  20. 20.

    Yanik E, Kaunitz G, Cottrell T, McMiller T, Ascierto M, Jessica E, et al. The local immune response against anal squamous cell carcinoma is similar in 2 HIV-infected and uninfected patients: implications for immunotherapy. JAMA Oncol. 2017;3:974-8.

    Article  Google Scholar 

  21. 21.

    Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol. 2015;23:32.

    CAS  Article  Google Scholar 

  22. 22.

    Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–71.

    CAS  Article  Google Scholar 

  23. 23.

    Bordeaux J, Johnson D, Sosman J, Kim JY, Vaupel C, Dabbas B, et al. Abstract 853: novel quantitative multiplexed PD-1/PD-L1 immunohistochemistry test provides superior prediction of treatment response in melanoma patients. Cancer Res. 2016;76:853.

    Article  Google Scholar 

  24. 24.

    Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4.

    CAS  Article  Google Scholar 

  25. 25.

    Galon J, Mlecnik B, Marliot F, Ou F-S, Bifulco CB, Lugli A, et al. Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: results of a worldwide consortium-based analysis of 1,336 patients. J Clin Oncol. 2016;34:3500.

    Article  Google Scholar 

  26. 26.

    Carstens JL, de Sampaio PC, Yang D, Barua S, Wang H, Rao A, et al. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat Commun. 2017;8:15095.

    Article  Google Scholar 

  27. 27.

    Carey CD, Gusenleitner D, Lipschitz M, Roemer MGM, Stack EC, Gjini E, et al. Topological analysis reveals a PD-L1-associated microenvironmental niche for reed-Sternberg cells in Hodgkin lymphoma. Blood. 2017;130:2420–30.

    CAS  Article  Google Scholar 

  28. 28.

    Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.

    CAS  Article  Google Scholar 

  29. 29.

    McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol. 2016;34:833–42.

    CAS  Article  Google Scholar 

  30. 30.

    Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 2013;73:128–38.

    CAS  Article  Google Scholar 

  31. 31.

    Webb JR, Milne K, Nelson BH. PD-1 and CD103 are widely Coexpressed on Prognostically favorable intraepithelial CD8 T cells in human ovarian Cancer. Cancer Immunol Res. 2015;3:926–35.

    CAS  Article  Google Scholar 

  32. 32.

    Lechner A, Schlößer H, Rothschild SI, Thelen M, Reuter S, Zentis P, et al. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma. Oncotarget. 2017;8:44418–33.

    Article  Google Scholar 

  33. 33.

    Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114:1537–44.

    CAS  Article  Google Scholar 

  34. 34.

    Dowlatshahi M, Huang V, Gehad AE, Jiang Y, Calarese A, Teague JE, et al. Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T-cell exhaustion in reducing T-cell responses. J Invest Dermatol. 2013;133:1879–89.

    CAS  Article  Google Scholar 

  35. 35.

    Giraldo NA, Becht E, Vano Y, Petitprez F, Lacroix L, Validire P, et al. Tumor-infiltrating and peripheral blood T-cell Immunophenotypes predict early relapse in localized clear cell renal cell carcinoma. Clin Cancer Res. 2017;23:4416–28.

    CAS  Article  Google Scholar 

  36. 36.

    Ahrends T, Spanjaard A, Pilzecker B, Bąbała N, Bovens A, Xiao Y, et al. CD4+ T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness. Immunity. 2017;47:848-61.

    Article  Google Scholar 

  37. 37.

    Teigler JE, Zelinskyy G, Eller MA, Bolton DL, Marovich M, Gordon AD, et al. Differential inhibitory receptor expression on T cells delineates functional capacities in chronic viral infection. J Virol. 2017:91.

  38. 38.

    Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545:60–5.

    CAS  Article  Google Scholar 

  39. 39.

    Kitano S, Tsuji T, Liu C, Hirschhorn-Cymerman D, Kyi C, Mu Z, et al. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol Res. 2013;1:235–44.

    CAS  Article  Google Scholar 

  40. 40.

    Haabeth OAW, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, et al. How do CD4(+) T cells detect and eliminate tumor cells that either lack or express MHC class II molecules? Front Immunol. 2014;5:174.

    Article  Google Scholar 

  41. 41.

    Ritter C, Fan K, Paulson KG, Nghiem P, Schrama D, Becker JC. Reversal of epigenetic silencing of MHC class I chain-related protein a and B improves immune recognition of Merkel cell carcinoma. Sci Rep. 2016;6:21678.

    CAS  Article  Google Scholar 

  42. 42.

    Roemer MGM, Advani RH, Redd RA, Pinkus GS, Natkunam Y, Ligon AH, et al. Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. Cancer Immunol Res. 2016;4:910–6.

    Article  Google Scholar 

  43. 43.

    Overacre-Delgoffe AE, Chikina M, Dadey RE, Yano H, Brunazzi EA, Shayan G, et al. Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity. Cell. 2017;169:1130–1141.e11.

    CAS  Article  Google Scholar 

  44. 44.

    Xiao X, Lao X-M, Chen M-M, Liu R-X, Wei Y, Ouyang F-Z, et al. PD-1hi identifies a novel regulatory B-cell population in human Hepatoma that promotes disease progression. Cancer Discov. 2016;6:546–59.

    CAS  Article  Google Scholar 

Download references


The authors would like to thank Clifford Hoyt from Perkin Elmer and Darren Locke from Bristol Myers Squibb for technical assistance, as well as Jessica Esandrio for administrative assistance.


This work was supported by the Melanoma Research Alliance (JMT, SLT); Bristol-Myers Squibb (JMT, SLT); Sidney Kimmel Cancer Center Core Grant P30 CA006973 (JMT); National Cancer Institute R01 CA142779 (JMT, SLT); NIH T32 CA193145 (TRC, AS, JES); NCI K24 CA139052 (PN); NIH Grant UM1 CA154967 (MAC); NIH/NCI Cancer Center Support Grant P30 CA015704; the Bloomberg-Kimmel Institute for Cancer Immunotherapy; the Cancer Immunotherapy Trials Network, and Stand Up To Cancer–Cancer Research Institute Cancer Immunology Translational Cancer Research Grant SU2C-AACR-DT1012. Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research.

Availability of data and materials

The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.

Author information




NAG and JMT contributed to the study concept and design, analysis and interpretation of the data, and drafting of the manuscript. All study authors were involved in data acquisition. NAG, LD, and JMT performed the statistical analyses. NAG, JES, SLT, and JMT contributed to the revisions of the final manuscript. All authors read and approved this manuscript.

Corresponding author

Correspondence to Janis M. Taube.

Ethics declarations

Ethics approval and consent to participate

Evaluation of archived pathology specimens described in this manuscript is covered under a study approved by the Johns Hopkins University Institutional Review Board which does not require individual patient consent.

Consent for publication

Not applicable.

Competing interests

EJL: consultant for Bristol-Myers Squibb, EMD Serono, Merck, Novartis; research funding from Bristol-Myers Squibb.

RAA: Bristol-Myers Squibb, Merck, Five Prime Therapeutics, Adaptive Biotechnologies.

SLT: consultant for Five Prime Therapeutics; stock options from Five Prime Therapeutics; research funding from Bristol-Myers Squibb.

JMT: consultant for Bristol-Myers Squibb, Amgen, Merck, AstraZeneca; research funding from Bristol-Myers Squibb

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Additional file

Additional file 1

Figure S1. CD8+ cell densities correlate with the presence of McPyV, but PD-1 densities do not correlate with viral status. Figure S2. PD-1+ cell densities in both the peritumoral and intratumoral regions correlate with anti-PD-1 response, but CD8+ cell densities in these regions do not. Figure S3. Pathologist scores for PD-L1 expression levels did not associate with response to anti-PD-1 in patients with MCC. Figure S4. Computer-assisted quantitation of PD-L1 in the PT and IT regions of tumor can help distinguish anti-PD-1 responders (R) from non-responders (NR). Figure S5. CD8+, PD-1+, and PD-L1+ TME cell densities by quartile from MCC patients receiving anti-PD1. Figure S6. The density of PD-L1+ cells adjacent to a PD-1+ cell correlates with clinical response to anti-PD-1. (PDF 611 kb)

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Giraldo, N.A., Nguyen, P., Engle, E.L. et al. Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. j. immunotherapy cancer 6, 99 (2018).

Download citation


  • PD-1
  • PD-L1
  • Merkel cell
  • Multispectral immunofluorescence
  • Pembrolizumab